Caxton Associates (New York)’s Charles River Laboratories CRL Stock Holding History

Caxton Associates (New York)’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-7,976	Closed	-$1.61M	–	532
2023 Q1	$1.61M	Buy	+7,976	New	+$1.81M	0.24%	75
2022 Q3	–	Sell	-1,555	Closed	-$333K	–	504
2022 Q2	$333K	Buy	+1,555	New	+$380K	0.03%	351
2018 Q4	–	Sell	-2,293	Closed	-$309K	–	316
2018 Q3	$309K	Buy	+2,293	New	+$283K	0.02%	318

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

Caxton Associates (New York)'s CRL Position: Q2 2023 in Review

Caxton Associates (New York) sold out of Charles River Laboratories (CRL) in Q2 2023, closing a stake of 7,976 shares — an estimated $1.61M sold.

Caxton Associates (New York) first reported a position in CRL in Q3 2018 and held it in 3 quarters. The position peaked at $1.61M in Q1 2023. 611 funds tracked by Wall St. Rank hold CRL as of Q2 2023.

Caxton Associates (New York) reported no remaining Charles River Laboratories position as of Q2 2023 after selling out during the quarter.
Caxton Associates (New York) sold 7,976 Charles River Laboratories shares in Q2 2023, an estimated $1.61M.
Caxton Associates (New York) first reported a position in Charles River Laboratories in Q3 2018 and held it in 3 quarters.
Caxton Associates (New York)'s Charles River Laboratories position peaked at $1.61M in Q1 2023.
611 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2023.

Based on Caxton Associates (New York)'s 13F filing for Q2 2023, filed 15 Aug 2023.